Skip to main content
. 2022 Jun 3;14(11):2781. doi: 10.3390/cancers14112781

Figure 3.

Figure 3

Comparison of Serum Galectin Levels of Breast Cancer Patients KIT Gene Mutation Status in Tumor Sample. (A) Serum levels of galectin-1, as determined by ELISA, were significantly higher in breast cancer patients with a mutation in the KIT gene. (B) Serum levels of galectin-3, as determined by ELISA, were significantly higher in breast cancer patients with a mutation in the KIT gene. (C) Serum levels of galectin-8, as determined by ELISA, were significantly higher in breast cancer patients with a mutation in the KIT gene. (D) Serum levels of galectin-9, as determined by ELISA, were significantly higher in breast cancer patients with a mutation in the KIT gene. (* p-value ≤ 0.05).